Newsletter | June 22, 2022

06.22.22 -- Mitigating Cell & Gene Therapy Manufacturing Risks

From The Editor
Featured Editorial
Industry Insights
How To Mitigate Cell And Gene Therapy Manufacturing Risks Amplified By The COVID-19 Pandemic

Understanding not only the limitations of a post-COVID-19 manufacturing landscape, but also developing strategies to help overcome these challenges, is critical to drive the future of next-generation CGTs.

Considerations For Your First Clinical Trial

For a small and emerging biopharma, moving into the clinical trial phase of development can be overwhelming, and clinical research organizations (CROs) do not typically manage the comprehensive clinical trial supply chain. Discover seven best practices to help ensure a successful trial.

Ensuring Resilience: How Life Sciences Is Reshaping Supply Chains In Response To COVID-19

Understand how the supply chain experience, severely affected by COVID-19, involving global workforce disruption, surging demand, and drug shortage notices, is shaping attitudes toward resilience.

Large-Scale LVV Production: Process Development To GMP Vector

Explore the key advantages of a proven approach to scale the lentiviral vector (LVV) production process (48L cf) in a bioreactor (200 L) without changing critical quality attributes (CQAs).

Accelerate The Development And Production Of Viral-Based Gene Therapies

The recent pandemic revealed that with the proper framework a drug product can be developed, clinically tested, and produced for hundreds of millions of patients in less than a year. 

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.